September 5, 2025ACS Nano

Carrier-Free Nanoprodrug Mediating Laser-Activable Chemotherapeutic Immunomodulation against Cancer

View Full Paper

Ask AI

Bookmark

The carrier-free nanoprodrug significantly enhances tumor immunogenicity and effector T cell recruitment.
Following laser activation, the prodrug releases gemcitabine, enabling more effective chemotherapy delivery.
Utilizing photodynamic therapy, the nanoprodrug induces immunogenic cell death, addressing the tumor microenvironment.
Importantly, minimal hemotoxicity was observed, suggesting a safer cancer treatment option with this approach.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This research demonstrates enhanced immunogenicity with a carrier-free nanoprodrug in tumors, indicating significant improvements in the chemotherapy approach.

Cite This Study

Gao et al. (2025) studied this question.

synapsesocial.com/papers/68c23887b210217d647782ec https://doi.org/10.1021/acsnano.5c08856

View Full Paper

Ask AI

Bookmark

Implication

This research demonstrates enhanced immunogenicity with a carrier-free nanoprodrug in tumors, indicating significant improvements in the chemotherapy approach.

Carrier-Free Nanoprodrug Mediating Laser-Activable Chemotherapeutic Immunomodulation against Cancer

Key Points

Discussion

Implication

Cite This Study

Carrier-Free Nanoprodrug Mediating Laser-Activable Chemotherapeutic Immunomodulation against Cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider